Recent progress in GM-CSF-based cancer immunotherapy

被引：171

作者：

Yan, Wan-Lun ^{[1
,2
]}

Shen, Kuan-Yin ^{[2
,3
]}

Tien, Chun-Yuan ^{[1
,2
]}

Chen, Yu-An ^{[3
]}

Liu, Shih-Jen ^{[1
,2
]}

机构：

[1] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan

[2] Natl Hlth Res Inst, Natl Inst Infect Dis & Vaccinol, 35 Keyan Rd, Zhunan Town 350, Miaoli County, Taiwan

[3] Yuanpei Univ Med Technol, Dept Hlth & Leisure Management, Hsinchu, Taiwan

来源：

IMMUNOTHERAPY | 2017年 / 9卷 / 04期

关键词：

cancer immunotherapy; GM-CSF; vaccine; COLONY-STIMULATING FACTOR; HERPES-SIMPLEX-VIRUS; T-CELL RESPONSES; DISEASE-FREE SURVIVAL; PHASE-III TRIAL; DENDRITIC CELLS; SUPPRESSOR-CELLS; METASTATIC MELANOMA; DOSE-ESCALATION; IN-VIVO;

D O I：

10.2217/imt-2016-0141

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Cancer immunotherapy is a growing field. GM-CSF, a potent cytokine promoting the differentiation of myeloid cells, can also be used as an immunostimulatory adjuvant to elicit antitumor immunity. Additionally, GM-CSF is essential for the differentiation of dendritic cells, which are responsible for processing and presenting tumor antigens for the priming of antitumor cytotoxic T lymphocytes. Some strategies have been developed for GM-CSF-based cancer immunotherapy in clinical practice: GM-CSF monotherapy, GM-CSF-secreting cancer cell vaccines, GM-CSF-fused tumor-associated antigen protein-based vaccines, GM-CSF-based DNA vaccines and GM-CSF combination therapy. GM-CSF also contributes to the regulation of immunosuppression in the tumor microenvironment. This review provides recommendations regarding GM-CSF-based cancer immunotherapy.

引用

页码：347 / 360

页数：14

共 88 条

[1]

Ali OA, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000359

[2] Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma [J].

Andtbacka, Robert H. I. ;

Kaufman, Howard L. ;

Collichio, Frances ;

Amatruda, Thomas ;

Senzer, Neil ;

Chesney, Jason ;

Delman, Keith A. ;

Spitler, Lynn E. ;

Puzanov, Igor ;

Agarwala, Sanjiv S. ;

Milhem, Mohammed ;

Cranmer, Lee ;

Curti, Brendan ;

Lewis, Karl ;

Ross, Merrick ;

Guthrie, Troy ;

Linette, Gerald P. ;

Daniels, Gregory A. ;

Harrington, Kevin ;

Middleton, Mark R. ;

Miller, Wilson H., Jr. ;

Zager, Jonathan S. ;

Ye, Yining ;

Yao, Bin ;

Li, Ai ;

Doleman, Susan ;

VanderWalde, Ari ;

Gansert, Jennifer ;

Coffin, Robert S. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (25) :2780-U98

[3] The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer [J].

Annels, Nicola E. ;

Shaw, Victoria E. ;

Gabitass, Rachel F. ;

Billingham, Lucinda ;

Corrie, Pippa ;

Eatock, Martin ;

Valle, Juan ;

Smith, David ;

Wadsley, Jonathan ;

Cunningham, David ;

Pandha, Hardev ;

Neoptolemos, John P. ;

Middleton, Gary .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2014, 63 (02) :175-183

[4] Inhaled Granulocyte-Macrophage Colony Stimulating Factor for First Pulmonary Recurrence of Osteosarcoma: Effects on Disease-Free Survival and Immunomodulation. A Report From the Children's Oncology Group [J].

Arndt, Carola A. S. ;

Koshkina, Nadya V. ;

Inwards, Carrie Y. ;

Hawkins, Douglas S. ;

Krailo, Mark D. ;

Villaluna, Doojduen ;

Anderson, Peter M. ;

Goorin, Allen M. ;

Blakely, Martin L. ;

Bernstein, Mark ;

Bell, Sharon A. ;

Ray, Kaylee ;

Grendahl, Darryl C. ;

Marina, Neyssa ;

Kleinerman, Eugenie S. .

CLINICAL CANCER RESEARCH, 2010, 16 (15) :4024-4030

[5] GM-CSF: From Growth Factor to Central Mediator of Tissue Inflammation [J].

Becher, Burkhard ;

Tugues, Sonia ;

Greter, Melanie .

IMMUNITY, 2016, 45 (05) :963-973

[6] DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) Elicits Long-term T-cell Responses in Patients With Recurrent Prostate Cancer [J].

Becker, Jordan T. ;

Olson, Brian M. ;

Johnson, Laura E. ;

Davies, James G. ;

Dunphy, Edward J. ;

McNeel, Douglas G. .

JOURNAL OF IMMUNOTHERAPY, 2010, 33 (06) :639-647

[7] A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients [J].

Cassaday, Ryan D. ;

Sondel, Paul M. ;

King, David M. ;

Macklin, Michael D. ;

Gan, Jacek ;

Warner, Tom F. ;

Zuleger, Cindy L. ;

Bridges, Alan J. ;

Schalch, Heidi G. ;

Kim, Kyung Mann ;

Hank, Jacquelyn A. ;

Mahvi, David M. ;

Albertini, Mark R. .

CLINICAL CANCER RESEARCH, 2007, 13 (02) :540-549

[8] PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine [J].

Cheever, Martin A. ;

Higano, Celestia S. .

CLINICAL CANCER RESEARCH, 2011, 17 (11) :3520-3526

[9] THE GAMMA-134.5 GENE OF HERPES-SIMPLEX VIRUS-1 PRECLUDES NEUROBLASTOMA-CELLS FROM TRIGGERING TOTAL SHUTOFF OF PROTEIN-SYNTHESIS CHARACTERISTIC OF PROGRAMMED CELL-DEATH IN NEURONAL CELLS [J].

CHOU, J ;

ROIZMAN, B .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (08) :3266-3270

[10]

Collichio FA, 2013, J CLIN ONCOL S, V31

← 1 2 3 4 5 6 7 8 9 →